168 related articles for article (PubMed ID: 24560438)
41. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
42. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
[TBL] [Abstract][Full Text] [Related]
43. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
44. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
[TBL] [Abstract][Full Text] [Related]
45. Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial.
Badaras R; Jovaisa T; Lapinskiene I; Ivaskevicius J
J Addict Med; 2020; 14(3):253-260. PubMed ID: 31609865
[TBL] [Abstract][Full Text] [Related]
46. Naltrexone shortened opioid detoxification with buprenorphine.
Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
[TBL] [Abstract][Full Text] [Related]
47. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
48. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
49. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
50. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
[TBL] [Abstract][Full Text] [Related]
51. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
Coviello DM; Cornish JW; Lynch KG; Boney TY; Clark CA; Lee JD; Friedmann PD; Nunes EV; Kinlock TW; Gordon MS; Schwartz RP; Nuwayser ES; O'Brien CP
Subst Abus; 2012; 33(1):48-59. PubMed ID: 22263713
[TBL] [Abstract][Full Text] [Related]
52. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
[TBL] [Abstract][Full Text] [Related]
53. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Grinenko AIa; Krupitskiĭ EM; Zvartau EE
Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
[TBL] [Abstract][Full Text] [Related]
54. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.
Mannelli P; Patkar AA; Peindl K; Gorelick DA; Wu LT; Gottheil E
Addict Biol; 2009 Apr; 14(2):204-13. PubMed ID: 18715283
[TBL] [Abstract][Full Text] [Related]
55. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
56. Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder.
Zavod A; Akerman SC; Snow MM; Tierney M; Sullivan MA
J Am Psychiatr Nurses Assoc; 2019; 25(4):272-279. PubMed ID: 30569814
[No Abstract] [Full Text] [Related]
57. Early outcomes following low dose naltrexone enhancement of opioid detoxification.
Mannelli P; Patkar AA; Peindl K; Gottheil E; Wu LT; Gorelick DA
Am J Addict; 2009; 18(2):109-16. PubMed ID: 19283561
[TBL] [Abstract][Full Text] [Related]
58. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
Marcus R; Bojko MJ; Mazhnaya A; Makarenko I; Filippovych S; Dvoriak S; Altice FL; Springer SA
J Subst Abuse Treat; 2018 Mar; 86():86-93. PubMed ID: 29415856
[TBL] [Abstract][Full Text] [Related]
59. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
60. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
